Virus News and Research

Latest Virus News and Research

Three cups of coffee per day reduce liver cancer risk by more than 50%

Coffee consumption reduces risk of hepatocellular carcinoma (HCC), the most common type of liver cancer, by about 40 percent, according to an up-to-date meta-analysis published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

23 Oct 2013

Sydney researchers plan to introduce rapid HIV and STI testing in pharmacies, dental surgeries

University of Sydney researchers are currently surveying community pharmacists and dentists to gauge their support to introduce rapid HIV and STI testing in pharmacies and dental surgeries, potentially increasing rates of early diagnosis.

22 Oct 2013

Scientists highlight novel way to develop universal influenza vaccine that can protect against multiple flu strains

A study led by St. Jude Children's Research Hospital scientists highlights a new approach for developing a universal influenza vaccine that could protect against multiple flu strains, including deadly pandemic strains. The research appears today in the advance online edition of the scientific journal Nature Immunology.

22 Oct 2013

Breast milk may protect babies from acquiring HIV infection, say researchers

A substance in breast milk that neutralizes HIV and may protect babies from acquiring HIV from their infected mothers has been identified for the first time by researchers at Duke Medicine.

22 Oct 2013

Parental perceptions pose major barrier to acceptance of HPV vaccination

A Mayo Clinic physician and two other pediatric experts say that parental perceptions pose a major barrier to acceptance of human papillomavirus (HPV) vaccination — and that many of those perceptions are wrong.

22 Oct 2013

UCLA receives $7M grant to investigate links between substance abuse and HIV among minority men

The National Institute on Drug Abuse has awarded UCLA a $7 million grant to investigate the links between substance abuse and HIV among Latino and African-American men who have sex with men.

22 Oct 2013

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

NanoViricides, Inc. (the "Company") reports that its optimized injectable FluCide® drug candidate was found to be well tolerated in a non-GLP small animal safety/toxicology study. This study is an important step in the drug development pathway for FluCide.

21 Oct 2013

Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

Inovio Pharmaceuticals, Inc. announced today that the safety, tolerability and immunogenicity of its therapeutic vaccine for hepatitis C (INO-8000/VGX-6150) will be studied in a phase I clinical trial in chronically HCV infected patients.

21 Oct 2013

Certain food and lifestyle habits can turn on or off expression of cancer related genes

Research performed at the Center of Research and Advanced Studies (Cinvestav) has identified that certain food and lifestyle habits can turn on or off the expression of cancer related genes.

21 Oct 2013

Whitehead Institute scientists discover insidious nature of influenza virus

Revealing influenza's truly insidious nature, Whitehead Institute scientists have discovered that the virus is able to infect its host by first killing off the cells of the immune system that are actually best equipped to neutralize the virus.

21 Oct 2013

Researchers design surface-scanning coil detector for direct bacteria detection on food surfaces

As anyone who has ever consumed bacteria-contaminated food and experienced "food poisoning" can tell you, it's a miserable experience. Yet it's an all-too-common one, with foodborne illnesses making 1 in 6 Americans -- or 48 million people -- sick each year. Of these people sickened, 128,000 end up in the hospital, according to the Centers for Disease Control and Prevention, while 3,000 die.

19 Oct 2013

Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

Medivir AB (OMX:MVIR-B) today announced preliminary data from two phase III studies conducted by Janssen R&D Ireland evaluating simeprevir in genotype 4 chronic hepatitis C in adult patients with compensated liver disease, and in genotype 1 hepatitis C and HIV-1 co-infected adult patients.

19 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Pfizer Inc. (NYSE:PFE) announced today that the European Commission approved updates to the Summary of Product Characteristics (SmPC) for the company's pneumococcal conjugate vaccine Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), regarding its use in certain populations at high risk of pneumococcal disease.

18 Oct 2013

HBV-infected men more likely to develop liver cancer

A team of researchers has identified a novel mutation in the hepatitis B virus (HBV) in Korea that appears only in men and could help explain why HBV-infected men are roughly five times more likely than HBV-infected women to develop liver cancer.

18 Oct 2013

Merck to present pharmacokinetic data on once-daily ISENTRESS at EACS

Merck, known as MSD outside the United States and Canada, is presenting pharmacokinetic data this week on investigational formulations of a once daily dose of ISENTRESS at the 14th European AIDS Conference, sponsored by the European AIDS Clinical Society.

17 Oct 2013

New method to display viral DNA in host cells at single-molecule resolution

The medical, humanitarian and economical impact of viral diseases is devastating to humans and livestock. There are no adequate therapies available against most viral diseases, largely because the mechanisms by which viruses infect cells are poorly known.

17 Oct 2013

Most U.S. adolescents lack antibodies that may help protect against genital herpes, says study

A new study suggests a growing number of U.S. adolescents lack antibodies that may help protect them later in life against an increasingly important cause of genital herpes. Published in The Journal of Infectious Diseases and available online, the findings show that fewer of today's teens have been exposed in their childhood to herpes simplex virus type 1 (HSV-1), a common cause of cold sores, than U.S. adolescents in previous years.

17 Oct 2013

New type of antibiotic kills multidrug-resistant germ common to health care settings

A new type of antibiotic called a PPMO, which works by blocking genes essential for bacterial reproduction, successfully killed a multidrug-resistant germ common to health care settings, UT Southwestern Medical Center researchers report.

16 Oct 2013

Janssen seeks European marketing approval for combination of once-daily darunavir with cobicistat

Janssen-Cilag International NV, today announced it has submitted a Marketing Authorisation Application to the European Medicines Agency seeking approval for a once-daily single tablet fixed-dose antiretroviral combination product containing darunavir, a protease inhibitor developed by Janssen, with cobicistat, a pharmacokinetic enhancer or boosting agent, developed by Gilead Sciences, Inc. for use in combination with other human immunodeficiency virus medicines.

15 Oct 2013

Virus News and Research

Latest Virus News and Research

Three cups of coffee per day reduce liver cancer risk by more than 50%

Sydney researchers plan to introduce rapid HIV and STI testing in pharmacies, dental surgeries

Scientists highlight novel way to develop universal influenza vaccine that can protect against multiple flu strains

Breast milk may protect babies from acquiring HIV infection, say researchers

Parental perceptions pose major barrier to acceptance of HPV vaccination

UCLA receives $7M grant to investigate links between substance abuse and HIV among minority men

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

Certain food and lifestyle habits can turn on or off expression of cancer related genes

Whitehead Institute scientists discover insidious nature of influenza virus

Researchers design surface-scanning coil detector for direct bacteria detection on food surfaces

Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

HBV-infected men more likely to develop liver cancer

Merck to present pharmacokinetic data on once-daily ISENTRESS at EACS

New method to display viral DNA in host cells at single-molecule resolution

Most U.S. adolescents lack antibodies that may help protect against genital herpes, says study

New type of antibiotic kills multidrug-resistant germ common to health care settings

Janssen seeks European marketing approval for combination of once-daily darunavir with cobicistat

A new way of characterising biomolecules eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in